

70. (As filed) The method of claim 69 wherein radiation therapy or chemotherapy is also administered to the mammal.

71. (As filed) The method of claim 70 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered concurrently.

72. (As filed) The method of claim 70 wherein the Apo-2 ligand polypeptide and the chemotherapy are administered sequentially.

73. (As filed) The method of claim 70 wherein the chemotherapy is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside, Cyclophosphamide, Thiotepa, Busulfan, Cytosin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, and Carboplatin.

74. (As filed) The method of claim 69 wherein said Apo-2 ligand polypeptide consists of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

75. (As filed) The method of claim 69 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

76. (As filed) The method of claim 74 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

77. (As filed) The method of claim 69 wherein said Apo-2 ligand polypeptide is unglycosylated.

78. (As filed) The method of claim 77 wherein said Apo-2 ligand polypeptide is produced in *E. coli*.

Please add the following claims:

--79. The method of claim 69 wherein said blastoma is glioblastoma multiforme.

80. A method of treating a mammal having glioblastoma multiforme, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's glioblastoma multiforme cells, wherein said Apo-2 ligand polypeptide is selected from the group consisting of:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1); and

(c) a polypeptide which is a fragment of (a) or (b).

DZ 81. The method of claim 80 wherein said Apo-2 ligand polypeptide consists of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

82. The method of claim 80 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

83. The method of claim 80 wherein said Apo-2 ligand polypeptide is unglycosylated.

84. A method of treating a mammal having glioblastoma multiforme, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's glioblastoma multiforme cells, wherein said Apo-2 ligand polypeptide comprises amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

85. The method of claim 84 wherein said Apo-2 ligand consists of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

D2 86. The method of claim 84 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

87. The method of claim 84 wherein said Apo-2 ligand polypeptide is unglycosylated. ---

---